Interleukin-18 in obesity and obesity-related metabolic diseases - PubMed (original) (raw)

Christian Stoess et al. Nat Rev Endocrinol. 2026 Jan.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: H.M.H. has consulted for Novartis, SOBI and Ventyx and has research collaborations with Regeneron, Jecure, Inapill and Zomagen. L.B. was a site principal investigator for Novartis, and speaker for SOBI. A.E.F. is an employee and stockholder of Pfizer. The remaining authors declare no competing interests.

References

    1. Landy, E., Carol, H., Ring, A. & Canna, S. Biological and clinical roles of IL-18 in inflammatory diseases. Nat. Rev. Rheumatol. 20, 33–47 (2024). -DOI -PubMed
    1. Netea, M. G. et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat. Med. 12, 650–656 (2006). -DOI -PubMed
    1. Zorrilla, E. P. et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc. Natl Acad. Sci. USA 104, 11097–11102 (2007). -DOI -PubMed -PMC
    1. Murphy, A. J. et al. IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome. Cell Metab. 23, 155–164 (2016). -DOI -PubMed
    1. Thornton, P. et al. The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model. Obesity 33, 1309–1321 (2025). -DOI -PubMed

LinkOut - more resources